XBiotech Results from Randomized Double-Blinded Phase 1/2 Study Suggest Potential Breakthrough Treatment for Advanced Pancreatic Cancer https://lnkd.in/gqqYKiEB
关于我们
XBiotech is a fully integrated global biosciences company dedicated to pioneering the discovery, development and commercialization of therapeutic antibodies based on its True Human™ proprietary technology. Unlike previous generations of antibody therapies, XBiotech’s True Human™ antibodies are 100 percent human, derived from individuals who possess natural immunity to certain diseases. With discovery and clinical programs across multiple disease areas, XBiotech’s True Human™ antibodies have the potential to harness the body’s natural immunity to fight disease with increased safety, efficacy and tolerability. XBiotech is currently advancing a robust pipeline of antibody therapies to exceed the standards of care in oncology, inflammatory conditions and infectious diseases. The Company's broad pipeline of True Human™ antibodies are able to potentially deliver unmatched safety and efficacy because they are cloned directly from individual donors who possess natural immunity against certain targeted diseases. As such, True Human™ antibodies retain their natural physiology and tolerance profile, having passed the rigors of immune selection in the body.
- 网站
-
http://www.xbiotech.com
XBiotech USA, Inc.的外部链接
- 所属行业
- 生物技术研究
- 规模
- 51-200 人
- 总部
- Austin,Texas
- 类型
- 上市公司
- 创立
- 2005
- 领域
- first-in-class monoclonal antibody
地点
-
主要
5217 Winnebago Ln
US,Texas,Austin,78744
XBiotech USA, Inc.员工
动态
-
XBiotech We Believe. https://lnkd.in/e7m_czeV
XBiotech We Believe
https://www.youtube.com/
-
XBiotech to Begin Constructing New R&D Facility on its 48-acre Campus https://lnkd.in/gbq-MaSK
XBiotech to Begin Constructing New R&D Facility on its 48-acre Campus | XBiotech
investors.xbiotech.com